News

Newsletter

Newsletter 2014.07 – ANVISA publishes resolutions on new procedures relative to marketing authorization in Brazil: RDC #58 and #60/2014

The main law regulating the health system in Brazil – Law #6,360 dated 1976 – establishes that each and every drug available in the pharmaceutical market must be approved by the Ministry of Health. Since the creation of the Brazilian FDA (called ANVISA), this autonomous autarchy subordinated to the Ministry of Health is in charge of issuing marketing authorization for drugs for human use and of establishing specific resolutions in order to regulate each of the existing categories of medicaments, such as the new drugs, generics, similars, biologicals.

According to ANVISA’s requirements, the documentation submitted by the manufacturers of both generic and similar drugs, upon applying for marketing approval, is significantly simplified compared to the reference product (the so-called “abridged process”), as only pharmaceutical equivalence and relative bioavailability/ bioequivalence assays are required to obtain approval for products pertaining to these categories.

It should be noted that, since the publication of Resolutions RDC #133 (new applications for marketing approval) and RDC #134 (similars, already approved), both dated May 29, 2003, ANVISA has begun to require proof of therapeutic equivalence also for similar drugs; therefore, it is estimated that all manufacturers of these products will have complied with such requirement by the end of 2014.

Accordingly, studies of pharmaceutical equivalence and bioavailability/bioequivalence became necessary in order to obtain marketing authorization for both generic and similar drugs, although the latter were not then yet considered to be interchangeable with the reference product.

Back

Last related news

June 7, 2024

BRPTO Publishes Integrity Plan for 2024-2025

On Tuesday, June 4, 2024, the Brazilian Patent and Trademark Office (”INPI”) published its Integrity Plan, outlining actions to manage integrity risks BRPTO Publishes Integrity Plan for 2024-2025

Ler notícia

May 29, 2024

New Regulation Approved by Anvisa Simplifies the Registration Process for Biosimilar Medicines

Anvisa approved the new simplified regulation for the registration of biosimilar medicines, whose publication in the Official Gazette (DOU) is still awaited. New Regulation Approved by Anvisa Simplifies the Registration Process for Biosimilar Medicines

Ler notícia

May 27, 2024

New Rules and Conditions for Obtaining Authorization for the Commercial Exploration of Sports Betting

On May 22, 2024, the Secretariat of Prizes and Bets of the Ministry of Finance (SPA/MF) published Ordinance No. 827/2024, which regulates New Rules and Conditions for Obtaining Authorization for the Commercial Exploration of Sports Betting

Ler notícia
plugins premium WordPress